Apocrine sweat gland disorder

This study tests a new drug called tulisokibart in 147 people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. Participants are randomly assigned to receive either the drug or a placebo, and researchers will check if the drug reduc…

This study tests a drug called bimekizumab in teenagers (ages 9 to 17) with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils. The goal is to see how the drug moves through the body and if it is safe. About 40 participants will receive the dr…

This phase 3 trial tests the drug lutikizumab against a placebo in about 1400 adults and teens with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and abscesses. Participants receive weekly shots for 16 weeks, then continue on differen…

This study tests a daily pill called ritlecitinib for adults with moderate to severe hidradenitis suppurativa (HS), a condition causing painful red skin lumps. About 240 participants who haven't been helped by antibiotics will be randomly assigned to get the drug or a placebo for…

This study looks at the long-term safety and effectiveness of the drug povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Participants have already completed 54 weeks of treatment in earlier studies. The goal is to monitor sid…

This phase 3 study tests an oral drug called remibrutinib in 565 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Participants receive one of two doses of remibrutinib or a placebo for 68 weeks. The main goal is to see …

This phase 3 trial tests an oral drug called remibrutinib in 588 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study compares two doses of the drug against a placebo over 68 weeks. The main goal is to see if the …

This study tests a daily pill called upadacitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils in the armpits, groin, and genital area. The trial includes about 1,328 adults and teens who have not improved with standard …

This phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …

This study tests a cream called ruxolitinib for people with mild to moderate hidradenitis suppurativa (HS), a chronic skin condition causing painful bumps and tunnels. About 550 participants will apply the cream or a placebo twice daily for several weeks. The main goal is to see …

This trial is investigating whether upadacitinib, an oral drug that blocks inflammation, can help people with moderate-to-severe hidradenitis suppurativa—a chronic skin disease causing painful lumps, abscesses, and scarring. Fifty adults will take upadacitinib daily for 24 weeks,…

This study follows 435 adults with moderate to severe hidradenitis suppurativa (a painful skin condition) who are taking secukinumab. Researchers want to see how doctors adjust the dose over two years and how well the treatment controls symptoms like abscesses and pain. The goal …

This Phase 2 trial tests tibulizumab, a dual-action antibody, in 225 adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants first receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 wee…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 835 adults and teens who completed an earlier sonelokimab study will receive the drug for an e…

This study tests a drug called sonelokimab in 35 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. The main goals are to see how the drug moves through the body and whether it is safe. Researchers wi…

This study follows 107 adults in Russia with moderate to severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) who are taking secukinumab as part of their normal care. Researchers will track how many patients see a 55% reduction in disease severity over…

This early-stage trial tests a single dose of a new biologic drug, SBT777101, in 24 adults with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful abscesses and tunnels). The main goal is to check safety and side effects at increasing dose level…

This phase 2 trial tests an investigational drug called lutikizumab (ABT-981) in about 210 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing lumps and abscesses. The main study includes people who have already tried and failed anti-TNF…

This study tests five different investigational drugs (iscalimab, LYS006, MAS825, remibrutinib, and ianalumab) in 248 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. The main goal is to see if these drugs reduce abscesses a…

This study tests a cream called ruxolitinib for people with mild to moderate hidradenitis suppurativa (HS), a condition causing painful bumps under the skin. About 550 adults with HS will use the cream or a placebo for several weeks to see if it reduces flare-ups and improves sym…

This study looks at how satisfied people with moderate to severe hidradenitis suppurativa (HS) are with a new medication called secukinumab, and how it affects their quality of life. About 48 adults in the UAE who are just starting secukinumab will fill out questionnaires over a …

This study planned to test a fractional ablative erbium laser on scarring caused by hidradenitis suppurativa (HS) in the armpit area. It was designed for adults with mild HS activity and visible scars. However, the trial was withdrawn before enrolling any participants, so no resu…

This study aimed to see if Botulinum Toxin-A (Botox) could help people with hidradenitis suppurativa, a painful skin condition. It planned to enroll adults with active armpit lesions of similar severity on both sides. However, the study was withdrawn before any participants were …

This study planned to test whether gentian violet, a common purple antiseptic, could reduce redness, drainage, and pain in people with hidradenitis suppurativa (HS). Participants would have applied the treatment once and returned a month later to report changes. However, the stud…

This study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …

This study follows 192 adults with hidradenitis suppurativa (a painful skin condition) who are starting secukinumab as part of their normal care. Researchers will ask patients to rate their pain, oozing, and bad smell after 12 months. The goal is to understand how the drug affect…